Review Article

Emerging therapies for Alzheimer's disease: The promise of disease-modifying drugs exploring recent breakthroughs in drugs aimed at slowing or halting the progression of Alzheimer's disease

Nitin Dumore

Department of Pharmacology, Dadasaheb Balpande college of Pharmacy, Nagpur, Maharashtra, India.

Correspondence:
Dr. Nitin Dumore, Department of Pharmacology, Dadasaheb Balpande college of Pharmacy, Nagpur, Maharashtra, India.
E-mail: nitingdumore@gmail.com

How to cite this article: Dumore N. Emerging therapies for Alzheimer's disease: The promise of disease-modifying drugs exploring recent breakthroughs in drugs aimed at slowing or halting the progression of Alzheimer's disease. Innov Pharm Planet (IP-Planet) 2024;12(1):1-4.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 17-01-2024
Date of Revision: 10-02-2024
Date of Acceptance: 12-02-2024

ABSTRACT

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder affecting approximately 50 million individuals worldwide, with significant implications for healthcare systems and society. Recent advancements in disease-modifying therapies, targeting key pathological features such as amyloid-beta plaques, tau protein tangles, and neuroinflammation, hold promise for altering the disease's progression. Current treatments mainly focus on symptom relief, lacking the ability to halt neurodegeneration. Emerging therapies such as aducanumab and lecanemab aim to reduce amyloid accumulation, while novel tau-targeting strategies are under investigation. Neuroinflammatory pathways are also being explored for potential therapeutic interventions. Despite challenges in clinical efficacy and trial designs, multi-target approaches and personalized medicine may enhance treatment outcomes. Ongoing research is essential to develop effective interventions that can improve patient quality of life and reduce the societal burden of AD.

Keywords: Alzheimer's disease, amyloid-beta, clinical trials, disease-modifying therapies, multi-target approaches, neurodegeneration, neuroinflammation, personalized medicine, tau protein

Introduction

Overview of Alzheimer's disease (AD)

Prevalence and impact on society

AD is the most common form of dementia, affecting approximately 50 million people worldwide. This number is expected to rise significantly as the population ages, leading to increased healthcare costs and societal burdens associated with caregiving and loss of productivity. The disease primarily manifests as progressive cognitive decline, impacting memory, language, and daily functioning, ultimately leading to a loss of independence and increased mortality.[1]

Access this article online

Website: https://innovationaljournals.com/index.php/ip | e-ISSN: 2348-7275

DOI: 10.31690/ipplanet.2024.v012i01.001

Current understanding of pathophysiology

AD is characterized by two main pathological features: Amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. The amyloid hypothesis suggests that the accumulation of Aβ triggers a cascade of neurodegenerative processes, including synaptic dysfunction and neuronal death. Inflammation, oxidative stress, and mitochondrial dysfunction are also implicated in the disease's progression, complicating the understanding of its pathophysiology.[2]

Importance of Disease-Modifying Therapies

Limitations of symptomatic treatments

Current treatments for AD primarily focus on alleviating symptoms rather than modifying the disease course. Cholinesterase inhibitors like donepezil have been standard therapies for

managing cognitive symptoms but do not halt or reverse the underlying neurodegeneration. These symptomatic treatments often provide only modest benefits and are limited in their effectiveness.

Goals of Disease Modification

Disease-modifying therapies aim to slow or halt the progression of AD by targeting its underlying pathology. The primary goals include:

- Reducing amyloid plaque formation: Drugs like aducanumab have been developed to target Aβ accumulation directly.
- Modulating tau pathology: Therapies targeting tau aggregation aim to prevent NFT formation.
- Addressing neuroinflammation: Anti-inflammatory agents are being explored to mitigate neuroinflammatory responses associated with AD.

Recent breakthroughs in drug development have shown promise in these areas, highlighting the potential for disease-modifying therapies to change the trajectory of AD.[3]

Recent Breakthroughs in Disease-Modifying Drugs

Aducanumab (aduhelm)

This monoclonal antibody targets aggregated forms of Aβ and has been shown to reduce amyloid plaques in clinical trials. However, its approval has been controversial due to mixed evidence regarding its clinical efficacy.[4]

Lecanemab (leqembi)

Another monoclonal antibody that targets soluble Aβ protofibrils, lecanemab has demonstrated a slowing of cognitive decline in early-stage AD patients in recent studies.[5]

Tau-targeting therapies

Several investigational drugs aim to inhibit tau aggregation or promote its clearance from the brain. These therapies are still in clinical trials but represent a critical area of research due to tau's strong correlation with cognitive decline.

Combination therapies

Researchers are exploring combinations of existing symptomatic treatments with new disease-modifying drugs to enhance overall efficacy and address multiple pathways involved in AD pathology.[2]

Pathophysiological Targets in AD

Amyloid-beta plaques

Role in disease progression

Amyloid-beta (Aβ) plaques are considered one of the hallmark features of AD. These plaques form from the aggregation of Aβ peptides, particularly the toxic Aβ42 variant, which disrupts neuronal communication and contributes to neurodegeneration. The accumulation of Aβ plaques is associated with cognitive decline and correlates with the severity of dementia symptoms. As plaques form, they trigger inflammatory responses and disrupt synaptic function, leading to neuronal cell death and brain atrophy.[6]

Mechanisms of plaque formation

The formation of amyloid plaques begins with the abnormal processing of amyloid precursor protein (APP), which is cleaved by enzymes such as β-secretase and γ-secretase, resulting in the production of Aβ peptides. An imbalance between Aβ production and clearance leads to the formation of oligomers, which are believed to be particularly neurotoxic. Over time, these oligomers aggregate into insoluble fibrils and ultimately form dense plaques that accumulate between neurons, exacerbating the disease's progression.

Tau protein and NFTs

Pathogenic role of tau

Tau protein stabilizes microtubules in neurons; however, in AD, tau becomes hyperphosphorylated, leading to its aggregation into NFTs. These tangles disrupt microtubule stability and impair intracellular transport, contributing to neuronal dysfunction and cell death. The presence of NFTs is closely linked to the severity of cognitive impairment in AD patients.[7]

Relationship between tau and neurodegeneration

The relationship between tau pathology and neurodegeneration is complex. While Aβ accumulation is often seen as an initiating factor in AD pathology, tau tangles appear to correlate more closely with neurodegenerative processes and clinical symptoms. As tau aggregates spread through the brain, they contribute to synaptic loss and cognitive decline, suggesting that targeting tau could be a critical strategy for disease modification.[4]

Neuroinflammation

Role of the immune system in Alzheimer's

Neuroinflammation is increasingly recognized as a key component of AD pathology. Activated microglia and astrocytes release pro-inflammatory cytokines in response to Aβ plaques and NFTs, which can exacerbate neuronal damage. This chronic inflammatory state may contribute to synaptic dysfunction and accelerate neurodegeneration, highlighting the immune system's dual role as both a protective and harmful player in AD.[8]

Potential for targeting neuroinflammatory pathways

Given the role of neuroinflammation in AD progression, there is growing interest in developing therapies that target inflammatory pathways. Modulating the immune response through anti-inflammatory agents or immunotherapies may help mitigate neuronal damage associated with chronic inflammation. Research is ongoing to identify specific targets within these pathways that could lead to effective disease-modifying treatments.[2]

Overview of Emerging Disease-Modifying Drugs

Anti-amyloid therapies

Monoclonal antibodies

Monoclonal antibodies such as aducanumab and lecanemab target amyloid-beta (Aβ) plaques, aiming to reduce their accumulation in the brain.

Mechanisms and clinical trial results

Aducanumab was designed to bind to aggregated forms of Aβ, showing a reduction in plaque levels in clinical trials. However, its approval faced significant controversy due to mixed results regarding cognitive benefits, leading to debates about its clinical efficacy and cost-effectiveness.[9]

Lecanemab, on the other hand, has demonstrated a 27% reduction in global cognitive decline compared to placebo in early-stage AD patients, marking a more favorable reception among the scientific community.[10]

Controversies and regulatory challenges

The approval of aducanumab by the Food and Drug administration was met with skepticism due to insufficient evidence of its effectiveness in improving clinical outcomes. This has raised ethical questions about regulatory practices and the implications for patient care.

Small molecules targeting amyloid processing

In addition to monoclonal antibodies, small molecules are being developed to modulate the processing of APP or enhance Aβ clearance. These compounds aim to prevent plaque formation at earlier stages of the disease and are currently undergoing various phases of clinical trials.

Anti-tau therapies

Tau aggregation inhibitors

Tau-targeting therapies focus on inhibiting tau aggregation, which is crucial for preventing NFTs. Several agents are in development, aiming to stabilize tau or prevent its pathological modifications.

Anti-tau monoclonal antibodies

Immunotherapies targeting tau, such as semorinemab, have been investigated but have shown limited efficacy in early trials. While some studies suggest that tau-targeting may correlate more closely with symptom severity than Aβ targeting, challenges remain regarding their overall clinical benefit.[11]

Neuroinflammatory modulators

Agents targeting microglial activation

Microglial activation plays a significant role in neuroinflammation associated with AD. New therapies are being developed to modulate this activation, potentially reducing neuroinflammatory damage and improving neuronal health.

Cytokine inhibitors and their implications

Cytokine inhibitors aim to reduce pro-inflammatory cytokine levels that contribute to neurodegeneration in AD. These agents could offer a dual benefit by addressing both inflammation and neuronal health, although their long-term effects and efficacy are still under investigation.

Clinical Trial Landscape

Key recent trials and their outcomes

Phase II and III trials of disease-modifying agents

Recent trials have focused on both anti-amyloid and anti-tau therapies, with mixed results regarding efficacy and safety profiles. For instance, the Alzheimer's Tau Platform (ATP) trial aims to evaluate combined therapies targeting both amyloid and tau pathways.[3]

Analysis of efficacy and safety profiles

While some therapies have shown promise in reducing biomarkers like Aβ or tau levels, translating these findings into meaningful clinical benefits remains a challenge.[12]

Challenges in trial design

Biomarker development for early detection

The lack of reliable biomarkers for early detection complicates patient recruitment for clinical trials aimed at disease modification. Advances in blood-based biomarkers may improve early identification of at-risk populations.[13]

Patient selection and outcome measures

Selecting appropriate patient populations and defining clear outcome measures are critical for assessing the efficacy of new treatments. Ongoing efforts aim to refine these parameters for better trial outcomes.

Future Directions and Perspectives

Combination therapies

Rationale for multi-target approaches

Combining therapies targeting different aspects of AD pathology – such as amyloid plaques, tau tangles, and neuroinflammation – may enhance treatment efficacy by addressing multiple pathways simultaneously.[8]

Ongoing studies exploring combinations

Studies like the ATP trial are pioneering this approach by evaluating combinations of anti-amyloid and anti-tau therapies.[1]

Personalized medicine

Genetic and biomarker profiling

Tailoring treatments based on genetic predispositions and biomarker profiles could optimize therapeutic outcomes for individual patients.

Tailoring treatments to individual patient profiles

Personalized approaches may lead to more effective interventions by considering each patient's unique disease characteristics.

Importance of early intervention

Identifying at-risk populations

Identifying individuals at risk for AD before significant cognitive decline occurs is crucial for implementing effective disease-modifying strategies.

Potential for preclinical treatment strategies

Preclinical interventions may significantly alter disease trajectories if initiated early enough, emphasizing the need for ongoing research in this area.

Ethical and Societal Considerations

Access and affordability of new therapies

As new treatments emerge, ensuring equitable access and affordability will be essential to maximize their societal impact.

Informed consent and patient autonomy

Ethical considerations surrounding informed consent processes must be prioritized, especially given the complexities involved in AD treatment decisions.

Public perception and education about Alzheimer's therapies

Increasing public awareness and understanding of emerging therapies will be vital for fostering support for ongoing research initiatives.

Conclusion

The landscape of AD treatment is shifting towards disease-modifying therapies targeting the underlying mechanisms of neurodegeneration. Despite challenges in demonstrating clear clinical benefits and managing side effects, these new therapies hold promise for altering the course of this devastating condition.

Emerging drugs aimed at amyloid-beta, tau protein, and neuroinflammation mark significant progress in Alzheimer's research.

These advancements offer hope for improving the quality of life for millions affected by AD.

Ongoing investment in research, collaboration among stakeholders, and innovative trial designs are essential for advancing our understanding and treatment of AD.

References

1. Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, *et al*. Alzheimer disease. Nat Rev Disease Primers 2021;7:33.
2. Bolognesi ML, Matera R, Minarini A, Rosini M, Melchiorre C. Alzheimer's disease: New approaches to drug discovery. Curr Opin Chem Biol 2009; 13:303-8.
3. Lakhan SE, Caro M, Hadzimichalis N. NMDA receptor activity in neuropsychiatric disorders. Front Psychiatry 2013;4:52.
4. Le AP, Tran TT, Cao TH, Le TM, Le PT, Huong HT. Evaluate and Optimize Cell-free RNA Extraction Methods to Apply for Alzheimer's Disease Biomarkers Detection. In 8th International Conference on the Development of Biomedical Engineering in Vietnam: Proceedings of BME 8, 2020, Vietnam: Healthcare Technology for Smart City in Low-and Middle-Income Countries. Springer International Publishing; 2022. p. 591-609.
5. Thakur AK, Kamboj P, Goswami K, Ahuja KJ. Pathophysiology and management of Alzheimer's disease: An overview. J Anal Pharm Res 2018;9:226-35.
6. Armstrong RA. Plaques and tangles and the pathogenesis of Alzheimer's disease. Folia Neuropathol 2006;44:1-11.
7. Huang J, Auchus AP. Diffusion tensor imaging of normal appearing white matter and its correlation with cognitive functioning in mild cognitive impairment and Alzheimer's disease. Ann N Y Acad Sci 2007;1097:259-64.
8. Murphy MP, LeVine H 3rd. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 2010;19:311-23.
9. Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, *et al*. The amyloid-β pathway in Alzheimer's disease. Mol Psychiatry 2021;26:5481-503.
10. Cummings JL, Osse AM, Kinney JW, Cammann D, Chen J. Alzheimer's disease: Combination therapies and clinical trials for combination therapy development. CNS Drugs 2024;38:613-24.
11. Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease: Current status and future directions. Nat Rev Neurol 2023;19:715-36.
12. Cullen NC, Novak P, Tosun D, Kovacech B, Hanes J, Kontsekova E, *et al*. Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: A post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. EBioMedicine 2024;99:1-13.
13. Panza F, Lozupone M. The challenges of anti-tau therapeutics in Alzheimer disease. Nat Rev Neurol 2022;18:577-8.